Junshi Bio's PD-1 Approved as First-line Therapy for Nasopharyngeal Carcinoma

Junshi Bio's anti-PD-1, toripalimab, was approved in China as a first-line treatment for recurrent or metastatic nasopharyngeal carcinoma. Earlier this month, Junshi out-licensed US-Canada rights for the anti-PD-1 antibody to Coherus Bio (NSDQ: CHRS) in an agreement worth up to $1.1 billion, including a $150 million upfront payment. It is the second China approval for toripalimab, which was the first China-developed PD-1 candidate authorized to launch. It was originally approved as a second-line treatment for melanoma.  More details.... Stock Symbol: (HK: 1877; SHA: 688180) Share this with colleagues: // //
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.